4DMedical Ltd
ASX:4DX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
4DMedical Ltd
PP&E Net
4DMedical Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
4DMedical Ltd
ASX:4DX
|
PP&E Net
AU$6.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
CogState Ltd
ASX:CGS
|
PP&E Net
$960.2k
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-4%
|
|
|
Pro Medicus Ltd
ASX:PME
|
PP&E Net
AU$3.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
24%
|
|
|
Alcidion Group Ltd
ASX:ALC
|
PP&E Net
AU$1.1m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
16%
|
CAGR 10-Years
60%
|
|
|
A
|
Artrya Ltd
ASX:AYA
|
PP&E Net
AU$1.5m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
123%
|
CAGR 10-Years
N/A
|
|
|
B
|
BlinkLab Ltd
ASX:BB1
|
PP&E Net
AU$147.5k
|
CAGR 3-Years
23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
4DMedical Ltd
Glance View
4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-08-07. The firm is focused on development of a non-invasive respiratory imaging solution using four-dimensional imaging. The firm's XV Technology is a four-dimensional lung imaging technology that utilizes mathematical models and algorithms to convert X-ray scans into quantitative data for physicians to manage patients with respiratory diseases and diseases of the lung. The XV Technology is accessible through a cloud-based software as a service (SaaS) platform that integrates with existing hospital equipment. The XV Technology Lung Ventilation Analysis Software (XV LVAS Ventilation) provides a non-invasive way of understanding regional lung motion and airflow. The company enables physicians to detect areas of high and low ventilation from all parts of the lung, in all phases of the breath.
See Also
What is 4DMedical Ltd's PP&E Net?
PP&E Net
6.6m
AUD
Based on the financial report for Dec 31, 2025, 4DMedical Ltd's PP&E Net amounts to 6.6m AUD.
What is 4DMedical Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
34%
Over the last year, the PP&E Net growth was -16%. The average annual PP&E Net growth rates for 4DMedical Ltd have been -12% over the past three years , 34% over the past five years .
